127 related articles for article (PubMed ID: 34171657)
1. Design, synthesis, biological evaluation and pharmacophore model analysis of novel tetrahydropyrrolo[3,4-c]pyrazol derivatives as potential TRKs inhibitors.
Wu T; Zhang C; Lv R; Qin Q; Liu N; Yin W; Wang R; Sun Y; Wang X; Sun Y; Zhao D; Cheng M
Eur J Med Chem; 2021 Nov; 223():113627. PubMed ID: 34171657
[TBL] [Abstract][Full Text] [Related]
2. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6
Pan S; Zhang L; Luo X; Nan J; Yang W; Bin H; Li Y; Huang Q; Wang T; Pan Z; Mu B; Wang F; Tian C; Liu Y; Li L; Yang S
J Med Chem; 2022 Feb; 65(3):2035-2058. PubMed ID: 35080890
[TBL] [Abstract][Full Text] [Related]
3. Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer.
Liu Z; Yu P; Dong L; Wang W; Duan S; Wang B; Gong X; Ye L; Wang H; Tian J
J Med Chem; 2021 Jul; 64(14):10286-10296. PubMed ID: 34253025
[TBL] [Abstract][Full Text] [Related]
4. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
[TBL] [Abstract][Full Text] [Related]
5. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.
Wang B; Zhang W; Liu X; Zou F; Wang J; Liu Q; Wang A; Hu Z; Chen Y; Qi S; Jiang Z; Chen C; Hu C; Wang L; Wang W; Liu Q; Liu J
Eur J Med Chem; 2020 Dec; 207():112744. PubMed ID: 32949955
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of aminopyridine derivatives as novel tropomyosin receptor kinase inhibitors.
Lv R; Wang X; Sun Y; Qin Q; Liu N; Wu T; Sun Y; Yin W; Zhao D; Cheng M
Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200438. PubMed ID: 36398500
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
8. Pyrazolo[1,5-a]pyrimidine based Trk inhibitors: Design, synthesis, biological activity evaluation.
Zhang Y; Liu Y; Zhou Y; Zhang Q; Han T; Tang C; Fan W
Bioorg Med Chem Lett; 2021 Jan; 31():127712. PubMed ID: 33246108
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
Duan Y; Wang J; Zhu S; Tu ZC; Zhang Z; Chan S; Ding K
Eur J Med Chem; 2020 Oct; 203():112552. PubMed ID: 32702585
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel indolin-2-one derivatives as potent second-generation TRKs inhibitors.
Qin Q; Fu Q; Wang X; Lv R; Lu S; Guo Z; Wu T; Sun Y; Sun Y; Liu N; Zhao D; Cheng M
Eur J Med Chem; 2023 May; 253():115291. PubMed ID: 37030091
[TBL] [Abstract][Full Text] [Related]
12. Novel 5,6-disubstituted pyrrolo[2,3-d]pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study.
Lee JH; El-Damasy AK; Seo SH; Gadhe CG; Pae AN; Jeong N; Hong SS; Keum G
Bioorg Med Chem; 2018 Nov; 26(21):5596-5611. PubMed ID: 30385226
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of macrocyclic derivatives as TRK inhibitors.
Li P; Cai S; Zhao T; Xu L; Guan D; Li J; Zhou J; Zhang H
Bioorg Med Chem Lett; 2021 Dec; 53():128409. PubMed ID: 34628036
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.
Lin T; Li J; Liu L; Li Y; Jiang H; Chen K; Xu P; Luo C; Zhou B
Eur J Med Chem; 2021 Apr; 215():113281. PubMed ID: 33611192
[TBL] [Abstract][Full Text] [Related]
15. Rational drug design to explore the structure-activity relationship (SAR) of TRK inhibitors with 2,4-diaminopyrimidine scaffold.
Wu T; Qin Q; Liu N; Zhang C; Lv R; Yin W; Sun Y; Sun Y; Wang R; Zhao D; Cheng M
Eur J Med Chem; 2022 Feb; 230():114096. PubMed ID: 35007864
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P
J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761
[TBL] [Abstract][Full Text] [Related]
17. Targeting tropomyosin receptor kinase for cancer therapy.
Miao Q; Ma K; Chen D; Wu X; Jiang S
Eur J Med Chem; 2019 Aug; 175():129-148. PubMed ID: 31077998
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
[TBL] [Abstract][Full Text] [Related]
19. Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
Abdelaziz AM; Diab S; Islam S; Basnet SKC; Noll B; Li P; Mekonnen LB; Lu J; Albrecht H; Milne RW; Gerber C; Yu M; Wang S
Med Chem; 2019; 15(6):602-623. PubMed ID: 30569866
[TBL] [Abstract][Full Text] [Related]
20. 2-Anilinoquinoline based arylamides as broad spectrum anticancer agents with B-RAF
El-Damasy AK; Haque MM; Park JW; Shin SC; Lee JS; EunKyeong Kim E; Keum G
Eur J Med Chem; 2020 Dec; 208():112756. PubMed ID: 32942186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]